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Abstract
Background: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal 
stage for early cancer detection. We applied quantitative proteomics to identify aberrantly elevated proteins in 
pancreatic juice samples derived from patients with PanIN3.
Results: Twenty proteins were found elevated in all three PanIN juices by at least two-fold. Among these proteins, 
anterior gradient-2 (AGR2) was found to be 2-10 fold elevated in PanIN3 juice samples analyzed by quantitative 
proteomics. An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum 
samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary 
Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis). AGR2 levels in the 
pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and 
IPMNs) as well as pancreatic cancer compared to control samples (p ≤ 0.03). By ROC analysis, the AGR2 ELISA achieved 
67% sensitivity at 90% specificity in predicting PanIN3 juice samples from the benign disease controls.
Conclusions: These results suggest that elevation of AGR2 levels in pancreatic juice occurs in early pancreatic cancer 
progression and could be further investigated as a potential candidate juice biomarker for early detection of pancreatic 
cancer.
Introduction
Pancreatic cancer is the fourth leading cause of cancer
death in the United States [1]. The poor prognosis could
potentially be improved by development of biomarkers
that could be used for early detection. Pancreatic intraep-
ithelial neoplasia or PanIN, represents the precursor
lesion for pancreatic ductal adenocarcinoma and is
graded 1-3, with PanIN3 representing the stage just
before cancer. Advanced PanIN lesions, e.g. PanIN3,
would be an ideal stage to diagnose patients, as this rep-
resents a time point when intervention and cure is possi-
ble.
Pancreatic juice is a proximal body fluid and represents
an opportune specimen for identifying biomarkers of
pancreatic cancer. Cancer cells are preferentially shed
into the ductal lumen, making juice a rich source of can-
cer associated markers. Previous studies have been con-
ducted to investigate telomerase, microRNA,
methylation, DNA mutation, and aberrant proteins as
potential biomarkers in pancreatic juice from patients
with pancreatic cancer or IPMNs (intraductal papillary
mucinous neoplasms) [2-10]. However, to our knowledge,
there has not been any study to evaluate pancreatic juice
samples from patients with PanIN3 lesions.
In this study, we first applied mass spectrometry based
quantitative proteomics to globally profile pancreatic
juice samples from patients with histologically confirmed
PanIN3 (referred as PanIN3 juice) to identify proteins
with differential expression level in comparison to juice
from benign disease controls. Among the differential pro-
teins revealed, AGR2 was elevated in all PanIN3 juice
samples analyzed. A recent study showed that AGR2 was
highly expressed in the tissue of both PanIN lesions and
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pancreatic cancer [11]. The same study also demon-
strated that AGR2 was secreted into culture media by
pancreatic cancer cells. To further investigate AGR2 lev-
els in pancreatic juice samples and sera, we developed
AGR2-specific monoclonal antibodies (mAbs) and an
ELISA to quantitatively detect AGR2 in pancreatic juice
and blood samples. We compared the AGR2 levels in
samples (juice and serum) from controls (including
benign diseases and chronic pancreatitis), patients with
pre-malignant lesions (PanIN2, PanIN3 and IMPNs), and
patients with pancreatic cancer. Statistical analyses were
used to determine significance between each sample
group, and the sensitivity and specificity of AGR2 in sep-
arating cases from controls.
Materials and methods
Specimens
The specimens were collected in accordance with
approved Human Subject's guidelines at the University of
Washington and Virginia Mason Medical Center. The
pancreatic juice samples were collected during endo-
scopic retrograde cholangiopancreaticography (ERCP)
and immediately stored at -80°C. The control juice sam-
ples were from: 1) 7 cancer-free patients who were under-
going evaluation of Sphincter of Oddi dysfunction; 2) 11
patients who have benign pancreatic diseases, such as
chronic pancreatitis. The PanIN2 juice samples were
obtained from 6 patients who had histologically proven
PanIN2 but without pancreatic cancer. The PanIN3 juice
samples were obtained from 9 patients who had histolog-
ically proven PanIN3 but without pancreatic cancer.
These patients with PanIN diagnoses had complete pan-
creas resection, and no cancer found in the pancreas[12].
The IPMN cases were benign to borderline without evi-
dence of malignancy. The pancreatic cancer juice samples
were from 8 patients who had pancreatic ductal adeno-
carcinoma including stages 2 to 4. The diagnosis of dis-
ease was made histologically or, in the case of the
controls, by imaging in combination with supporting lab-
oratory values. The patient demographics are presented
in Table 1. Serum samples were obtained in red top tubes
and processed within 4 hours using a uniform protocol.
Once processed the serum was stored at -80°C and no
more than 2 freeze thaw cycles were allowed for a speci-
men used in the ELISA studies. Six sera from patients
with PanIN2-3 and 9 sera from pancreatic cancer patients
were included in this study for AGR2 serum ELISA test-
ing. The 9 healthy control sera were purchased from
Innovative Research (Southfield, MI).
Quantitative proteomics
The 4-plex iTRAQ (isobaric tags for relative and absolute
quantification) method [13] was applied in combination
with tandem mass spectrometry for quantitative profiling
of the pancreatic juice proteome from PanIN3 cases and
normal control. The control sample was generated by
pooling equal volume of 5 pancreatic juice samples from
patients with benign disease. Three hundred microliters
of pancreatic juice samples from pooled normal juice, and
three separate PanIN3 cases (a, b, and c) were subjected
to iTRAQ labeling followed by mass spectrometer analy-
sis using similar methods as previously described[14].
The MS/MS data were analyzed and processed using
Trans-Proteomic Pipeline (TPP). All of the MS/MS spec-
tra were searched against IPI human protein database
(v3.38) using the SEQUEST algorithm[15]. The database
search results were validated using the PeptideProphet
[16] and ProteinProphet [17]. ProteinProphet probability
score > 0.9 was used as the cut-off value for protein iden-
tification to ensure that the false positive rate (error rate)
for protein identification was < 0.9%. iTRAQ quantifica-
tion on peptide and protein abundance was achieved
using LIBRA program[18]. More information about
Trans-Proteomic Pipeline, PeptideProphet, Protein-
Table 1: Patient demographics in pancreatic juice
Benign
(N = 18)
Premalignant
(N = 25)
Pancreatic 
cancer
(N = 8)
Age
Mean 47.75 54.88 69.5
Range 18-73 25-79 46-77
Sex
Male 4 12 3
Female 14 13 3
Unknown 0 0 2
Benign
Sphincter of Oddi 7
Chronic pancreatitis 11
Premalignant
PanIN2 6
PanIN3 9
IPMN 10
Malignant
stage 2 1
stage 3 3
stage 4 2
stage undetermined 2Chen et al. Molecular Cancer 2010, 9:149
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Prophet, LIBRA and other programs can be obtained
from the Seattle Proteome Center http://tools.proteome-
center.org.
Production of recombinant AGR2 protein and monoclonal 
antibodies
A cDNA encoding AGR2 protein (21-175 aa) was reverse
transcribed from the OVCAR-3 cell line (ATCC, Manas-
sas, VA) and verified by DNA sequence analysis. Recom-
binant AGR2 protein (rAGR2) was expressed in
Escherichia coli with a GST tag and purified on GSTrap
columns (GE Healthcare, Fairfield, CT) using the AKTA
Prime (GE Healthcare) purification system. Full length,
GST-tagged recombinant AGR3 (rAGR3) protein was
purchased (Novus Biologicals, Littleton, CO). rAGR2 was
used to immunize BALB/c mice, and spleens from mice
with high-titer antibody responses to AGR2 were used to
develop mAbs using standard hybridoma technology.
H y b r i d o m a s  w e r e  c l o n e d  b y  l i m i t i n g  d i l u t i o n ,  a n d  t h e
supernatants from each hybridoma were screened against
the GST-tagged immunogen and, as negative controls,
other irrelevant GST-tagged recombinant proteins. mAb
affinities for AGR2 were evaluated with a Biacore X100
instrument (GE Healthcare).
AGR2 immunoprecipitation and mass spectrometric 
identification
To ensure that the newly developed AGR2.43 mAb was
binding specifically to AGR2 protein, we performed an
immunoprecipitation using this antibody and then
sequenced the immunoprecipitated product using mass
spectrometry. OV90 cell line lysate was used as the
source of AGR2. OV90 cell line lysate (1 mg in 1 ml) was
pre-cleared by incubation with 50 ul of Protein G resin
(Pierce, Rockford, IL) for 30 minutes at 4°C with shaking.
Protein G was pelleted by centrifugation and discarded.
Five microgram of AGR2.43 antibody was coupled to 50
ul of Protein G resin by incubation for 1 hour at 4°C with
shaking. The AGR2 antibody-Protein G complex was
centrifuged, washed in PBS, centrifuged again and added
to the pre-cleared OV90 cell line lysate and incubated for
2 hours at 4°C with shaking. The complex was washed
and centrifuged 3 times and resuspended in PBS. The
complex was dissociated from protein G by incubation
with 50 ul of 100 mM glycine at pH 2.5. Following centrif-
ugation and removal of the protein G pellet, the remain-
ing sample was neutralized by addition of 1 M Tris-HCl
pH 8.5 and further prepared as described below for Mass
Spectrometry analysis.
The AGR2 immunoprecipitated pull-down product
was buffer exchanged with 50 mM sodium bicarbonate,
reduced with 20 mM dithiothreitol at 37°C for 1 hour and
incubated with 20 mM iodoacetamide in the dark for 30
minutes to block the cysteine groups. The proteins were
then digested with trypsin (Promega, Madison, WI) at a
1:50 ratio for 18 hours at 37°C. The obtained peptides
were purified with a C18 column (The Nest Group,
Southborough, MA) and subjected to LC MS/MS analysis
using a linear ion trap mass spectrometer (LTQ, Ther-
moFinnigan, San Jose, CA). The resulting data was
searched against IPI human protein database V. 3.38 for
peptide and protein identification using SEQUEST algo-
rithm. A 1% false positive rate based on ProteinProphet
was used as a cut-off value for protein identification.
Western Blotting
Cells from the human pancreatic cancer cell lines
CFPAC-1 and MiaPaca were harvested and treated with
lysis buffer (PBS; 0.05% TritonX-100) including protease
inhibitor cocktail (Roche, Mannheim, Germany). Follow-
ing sonication and centrifugation, cell lysate supernatants
were quantified using a BCA quantification kit (Sigma,
Oakville, ON, Canada) and stored at -80°C. Ten micro-
grams of cell line lysate and 10 nanograms of rAGR2 or
rAGR3 were separated using NuPAGE Novex 4%-12%
Bis-Tris gels at 200V for 40 minutes and transferred to
nitrocellulose using the XCell SureLock Mini-Cell (Invit-
rogen) at 30V for 60 minutes. Membranes were blocked
overnight in blocking buffer (50 mM Tris; 150 mM NaCl;
5% skim milk powder). Membranes were then incubated
with 2 μg/ml AGR2.43 in blocking buffer with 0.1%
Tween-20 for 4 hours, washed three times in TBST (50
mM Tris; 150 mM NaCl; 0.1% Tween-20), incubated for 1
hour in Goat anti-mouse IR-800 (LI-COR, Lincoln, NE),
washed again and visualized with the Odyssey infrared
imager (LI-COR). As a loading control, the same mem-
brane was further probed with an anti-GAPDH antibody
(STEMCELL Technologies, Vancouver, Canada), rep-
robed with Goat anti-mouse IR-800 and imaged on the
Odyssey infrared imager.
AGR2 ELISA
To develop the ELISA, antibody pairs were identified
using hybridoma supernatants from AGR2 specific hybri-
doma clones with a Biacore X100 instrument (GE Health-
care). Mouse IgGs were purified using a protein G
column (GE Healthcare) and labeled with biotin using a
kit (Thermo Scientific). The mAb pair (mAbs AGR2.43
and AGR2.44) that showed the best sensitivity to specifi-
cally detect rAGR2 in both 1× Reagent Diluent (RD; R&D
Systems, Minneapolis, MN) and in RD supplemented
with 10% normal human serum (NHS) was selected. A
sandwich ELISA was established using mAb AGR2.43 as
capture, mAb AGR2.44 as detector and Superblock
(Thermo Scientific) as blocking buffer. The ELISA was
further optimized by determining the optimal incubation
time and the concentration of the capture and detector
antibody, the streptavidin-alkaline phosphatase conjugateChen et al. Molecular Cancer 2010, 9:149
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(Applied Biosystems Inc, Foster City, CA) and the chemi-
luminescent CSPD® Substrate to achieve the highest sen-
sitivity.
To assess the performance characteristics of the AGR2
ELISA, we tested serially diluted rAGR2 protein (from 40
ng/ml to 0.055 ng/ml in RD or RD+10%NHS) and diluted
human serum and cell line lysates (diluted 1/10 in RD) in
triplicate in three independent ELISA experiments. For
each experiment, a five-parameter log-logistic (5PL) stan-
dard curve was generated using EnVision software ver-
sion 1.12 and GraphPad Prism, and used to back-
calculate the concentration of the rAGR2 standards and
AGR2 levels in the human serum samples and cell line
lysates. The means, signal-to-noise (S:N) ratios, intra-
and inter-assay standard deviations (SD), and percent
coefficient of variances (%CV) were calculated.
AGR2 ELISAs were performed by researchers who
were blinded to the case/control status of specimens.
Costar white high binding 96 well plates (Corning, Corn-
ing, NY) were coated with 100 μl/well of 1.25 μg/ml puri-
fied mAb AGR2.43 in 0.1 M carbonate buffer (33.5 mM
Na2CO3, 0.1 M NaHCO3, pH 9.6) and incubated over-
night at 4°C. Plates were blocked with 200 μl/well of
Superblock (Pierce, Rockford, IL) and incubated at room
temperature (RT) for 2.5 hours. Plates were washed with
a protocol including six wash steps in TBST using a Skan-
washer plate washer (Molecular Devices, Union City,
CA). Patient serum, control serum or pancreatic juice
was diluted 1:10 in RD and incubated for 2 hours at RT
on a shaker. All samples and controls were assayed in
duplicate. Plates were washed and incubated with 100 μl
per well of 0.25 μg/ml biotinylated mAb AGR2.44 in
TBST for 2 hours at RT with shaking. Plates were washed
and incubated with 100 μl per well streptavidin-alkaline
phosphatase conjugate at 1:2500 in TBST for 1 hour on a
shaker at RT. After washing, the plates were incubated
with 100 μl/well of 0.4 mM chemiluminescent CSPD®
Substrate with Emerald-II™ Enhancer (Applied Biosys-
tems) at RT for 20 min in the dark, read on an EnVision
multilabel plate reader (PerkinElmer, Waltham, Massa-
chusetts), and analyzed using Envision software 1.12.
Immunohistochemistry (IHC)
Pancreatic tissues from 2 PanINs, 2 pancreatic cancers
and 2 cancer free controls were analyzed by IHC. Pancre-
atic tissue blocks were sectioned at 5 μm onto slides and
incubated for 30 minutes at 58°C. The slides were depar-
affinized before placing in a Ventana Discovery XT
autostainer (Ventana, Tucson, AZ) for immunohis-
tochemical staining. Antigen retrieval was performed
with a Ventana's standard CC1 protocol. The slides were
first incubated with mAb AGR2.43 for 60 minutes, and
the appropriate cross-adsorbed, biotinylated secondary
antibody (Jackson Immunoresearch, West Grove, PA)
was applied for 32 minutes. Bound antibodies were
detected using the DABMap kit (Ventana), counter-
stained with hematoxylin (Ventana), and coverslipped
manually with Cytoseal-60 (Richard Allan, Kalamazoo,
MI). T wo slides from each tissue block were stained in
separate experiments. The specificity of mAb AGR2.43
was confirmed by blocking experiments. Specifically,
incubation of mAb AGR2.43 with rAGR2, but not
r A G R 3 ,  r e s u l t e d  i n  l o s s  o f  s i g n a l  i n  s u bs e q u e n t  A G R 2
IHC staining.
Statistical analysis
For the purpose of statistical analysis, variables regarding
patient diagnostics were grouped in the following man-
ner: control (including all benign diseases from patients
undergoing a work-up for Sphincter of Oddi dysfunction,
and patients with pancreatitis), premalignant lesions
(including PanIN2, PanIN3, and IPMNs), and malignant
cancer groups (Table 1). Statistical analyses were per-
formed using GraphPad Prism (La Jolla, CA). Differences
i n  t h e  A G R 2  l e v e l s  b e t w e e n  g r o u p s  o f  p a t i e n t s  w e r e
tested for statistical significance using the Mann-Whit-
ney test in case of two groups and the Kruskal Wallis test
in case of more than two groups, respectively. Empirical
receiver operating characteristic (ROC) curves were used
to determine the sensitivity and specificity of AGR2 in
separating cases from controls. ROC curve shows the
trade-off between sensitivity and specificity as the thresh-
old for defining a positive test is varied. Generalized lin-
ear models were used to test for association between the
AGR2 values in serum and pancreatic juice. Statistical
significance was defined as P < 0.05.
Results
Identification of elevated proteins in pancreatic juice 
samples from patients with PanIN3 by quantitative 
proteomics
Quantitative proteomics analysis using stable isotope
labeling (iTRAQ) and tandem mass spectrometry was
applied to identify proteins abnormally elevated in the
pancreatic juice samples from PanIN3 patients. A pool of
5 control pancreatic juice samples was used as a control
for quantitative comparison. We identified twenty pro-
teins displaying elevated levels by at least two-fold in all
three PanIN3 juices when compared to normal control
juice (Table 2). Among these elevated proteins, anterior
gradient-2 (AGR2) was elevated by 10.47 ± 0.01; 3.96 ±
0.03; and 2.04 ± 0.01 folds in the three PanIN3 pancreatic
juice samples respectively, comparing to the pooled con-
trol sample (Figure 1). A recent study using IHC showed
that AGR2 was highly expressed in both PanINs and pan-
creatic cancer tissues and is secreted into the culture
media of pancreatic cancer cell lines [11]. This, togetherChen et al. Molecular Cancer 2010, 9:149
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with our results, prompted us to further investigated
AGR2 for its utility as a biomarker for pancreatic cancer.
Production and evaluation of AGR2 antibodies
We generated multiple hybridoma clones producing anti-
bodies specific for AGR2. Purified mAbs from these
hybridomas were then assessed for their specificity to
AGR2 using Western blotting, mass spectrometry, ELISA
and IHC. By Western blot, mAb AGR2.43 detected the 45
kDa GST-tagged rAGR2, but not GST-tagged rAGR3
protein (Figure 2). This antibody also detected a 20 kDa
protein corresponding to the predicted molecular weight
o f  n a t i v e  A G R 2  i n  t h e  c e l l  l y s a t e  o f  C F P A C - 1 ,  w h i c h
expresses a high level of AGR2, but not in the pancreatic
cancer cell line MiaPaca, which expresses a low level of
AGR2 (Figure 2), nor in the normal pancreatic ductal cell
line HPDE (data not shown). mAb AGR2.44 likely detects
a discontinuous epitope as the antibody failed to detect
Figure 1 Identification and quantification of AGR2 in pancreatic juice by iTRAQ labeling and tandem mass spectrometry. Two unique pep-
tides (HLSPDGQYVPR and LYAYEPADTALLLDNMK) from AGR2 were identified; the MS/MS spectra are presented in panel A and panel B respectively. 
The inserts are the iTRAQ reporting peaks at 114, 115, 116 and 117 representing relative intensity of the 4 samples compared: 114, pooled normal 
control juices; 115-117 were from PanIN case a, case b and case c respectively.C
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Table 2: Abnormally elevated proteins identified in PanIN3 juices by quantitative proteomics (by at least two-fold change)
gene symbol protein description ratio PanIN3 
case a vs normal
PanIN3 case a SEM ratio PanIN3 case 
b vs normal
PanIN3 case b SEM ratio PanIN3 case 
c vs normal
PanIN3 case c SEM
AGR2 Anterior gradient-2 10.47 0.03 3.96 0.01 2.04 0.01
HIST1H2B Histone H2B 34.78 0.04 8.53 0.03 10.01 0.01
LYZ Lysozyme C 27.56 0.02 3.70 0.01 2.05 0.01
MUC5AC Mucin-5AC 31.06 0.01 3.83 0.00 4.54 0.00
CA2 Carbonic anhydrase 2 9.58 0.02 3.18 0.01 1.97 0.01
KLK1 Kallikrein-1 3.25 0.06 3.12 0.08 11.52 0.02
ANXA5 Annexin A5 21.46 0.01 4.43 0.01 9.70 0.01
HIST2H4A Histone H4 41.77 0.01 9.82 0.01 11.88 0.01
ANXA4 Annexin A4 18.39 0.02 4.28 0.01 5.11 0.01
ACTB Actin, cytoplasmic 1, 2 17.98 0.01 6.13 0.01 4.41 0.01
SERPINA1 Alpha-1-antitrypsin 11.03 0.04 4.30 0.02 1.99 0.02
KRT8 Keratin, type II cytoskeletal 8 19.25 0.02 4.26 0.01 3.72 0.01
PRSS1 PRSS1 protein 4.56 0.01 15.35 0.02 30.46 0.03
YWHAE 14-3-3 protein epsilon 15.60 0.02 4.48 0.01 2.42 0.01
PPIA;LOC654188;PPIA
L3
Peptidyl-prolyl cis-trans 
isomerase A
13.93 0.02 5.05 0.02 4.04 0.01
PSIP1 PC4 and SFRS1-interacting 
protein
2.68 0.01 17.91 0.00 12.16 0.01
AKR1B10 Aldo-keto reductase family 1 
member B10
14.60 0.01 8.32 0.01 5.01 0.00
CLIC1 Chloride intracellular channel 
protein 1
5.84 0.04 3.22 0.04 4.08 0.04
C2 Complement C2 4.94 0.01 24.53 0.02 17.69 0.03
HNRNPA2B1 Heterogeneous nuclear 
ribonucleoproteins
7.13 0.04 2.64 0.01 2.51 0.04Chen et al. Molecular Cancer 2010, 9:149
http://www.molecular-cancer.com/content/9/1/149
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the expected AGR2 band. mAb AGR2.43 was then used
to immunoprecipitate proteins from the cell line OV90,
and the immunoprecipitated proteins were analyzed by
mass spectrometry. This revealed ten unique peptides
covering 43% of the AGR2 protein; no peptides from the
related protein AGR3 were detected (Table 3), suggesting
no cross reactivity to AGR3. By ELISA, we could detect
rAGR2 at concentrations as low as 0.055 ng/ml (Figure 3
and Table 4). In contrast, we failed to detect rAGR3 at
concentrations of 4, 20, 100 or 500 ng/ml (data not
shown). As expected, the ELISA detected higher levels of
AGR2 protein in lysates from CFPAC-1 cells (120.7 ng/
ml) compared to MiaPaca cells (14.6 ng/ml) (Table 4). By
IHC, mAb AGR2.43 reacted with tissue sections from
human PanINs and pancreatic cancer cases but not nor-
mal pancreatic epithelium (Figure 4B). Taken together,
these data confirm that mAb AGR2.43 is specific to
AGR2 and can be used for multiple applications.
Performance characteristics of the AGR2 ELISA
We evaluated the AGR2 ELISA in different sample matri-
ces using rAGR2, lysates from CFPAC-1 and MiaPaca cell
lines, and a human serum sample. A 5PL standard curve
was generated for each experiment and used to back-cal-
culate the concentration of the rAGR2 standards and cal-
culate AGR2 levels in lysates and serum. Figure 3 shows a
standard curve of rAGR2 ranging from 0.006 ng/ml to 40
ng/ml. The curve produced an r-squared of 0.999 demon-
strating a good fit to the 5PL curve. The limit of detec-
tion, calculated as the mean value for the blank controls
plus two standard deviations was 0.024 ng/ml. The aver-
age signal to noise (S:N) ratios calculated from three sep-
arate experiments ranged from 3559 (40 ng/ml standard)
to 6.2 (0.055 ng/ml standard) suggesting a limit of detec-
tion of at least 0.055 ng/ml AGR2 (Table 4). The intra-
and inter-assay SD were calculated, and CVs ranged from
1.5%-5.9% and 1.6%-9.1%, respectively. CFPAC-1 and
MiaPaca lysates and the human serum sample were
determined to have 120.7 ng/ml, 14.6 ng/ml and 22.0 ng/
ml AGR2 with intra-assay CVs of 6.8%, 5.4% and 6.2%
respectively and inter-assay CVs of 4.3%, 6.8% and 16%
respectively (Table 4). To assess the effects of serum on
the AGR2 ELISA, we added 10% Normal Human Serum
(NHS) to a subset of samples. The resulting standard
Figure 2 Detection of AGR2 by Western blot with mAb AGR2.43. 
A, Western blot of lysates from the human pancreatic cancer cell lines 
CFPAC-1 and MiaPaca, recombinant GST-tagged AGR2 (rAGR2) and 
AGR3 (rAGR3). As expected, mAb AGR2.43 detected the AGR2 protein 
(20 kDa) in CFPAC-1, but not MiaPaca lysates. The mAb also detected 
rAGR2 (45 kDa) but not rAGR3 (45 kDa). Note that rAGR2 and rAGR3 are 
of a higher molecular weight than their native counterparts because 
they carry a GST tag. B, Coomassie stained gel showing equivalent 
loading (1 μg each) of GST-tagged rAGR2 and rAGR3 proteins.
Figure 3 AGR2 ELISA standard curves. rAGR2 was diluted in either 
1× Reagent Diluent (RD) or RD supplemented with 10% normal human 
serum (RD+10%NHS). A 3-fold dilution series of rAGR2 (from 40 ng/ml 
to 0.006 ng/ml) was generated in RD or RD+NHS. AGR2 ELISA was used 
to measure the signal for each sample in RD (closed circles) or 
RD+10%NHS (closed squares). Standard curves were generated for 
AGR2 in RD (solid line) or RD+10%NHS (dashed line) using the five-pa-
rameter log-logistic method (r2 = 0.999 for both curves). The average of 
three replicates is presented. Error bars represent one standard devia-
tion and are almost not apparent due to low intra-assay standard devi-
ations.Chen et al. Molecular Cancer 2010, 9:149
http://www.molecular-cancer.com/content/9/1/149
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curve produced an r-squared of 0.999 and closely mir-
rored the standard curve determined without serum (Fig-
ure 3).
Correlation of AGR2 levels in pancreatic juice with its 
overexpression in neoplastic pancreas tissue
We next examined AGR2 expression by IHC in pancre-
atic tissues corresponding to the pancreatic juice samples
from cases a and c in the above quantitative proteomics
analysis. As shown in Figure 4B, AGR2 was highly
expressed in the PanIN ducts from both PanIN cases a
and c, and also highly expressed (strong staining) in pan-
creatic cancer, but not in normal pancreas epithelium
(negative staining). Thus, the elevation of AGR2 level in
the pancreatic juice was correlated with high expression
in PanIN ducts. Previous study had reported high expres-
sion of AGR2 in neoplastic cells with 98% (56 of 57) posi-
tivity on pancreatic cancer and minimal staining in
normal and pancreatitis tissues [11]. Our current study
suggests that the detected AGR2 in pancreatic juices is
likely originated from the pancreas.
Significant elevation of AGR2 levels in the pancreatic juice 
samples from patients with pre-malignant pancreatic 
neoplasia
W e used ELISA to measure AGR2 levels in pancreatic
juice samples from patients with benign pancreatic dis-
eases (n = 18; including chronic pancreatitis), premalig-
nant pancreatic neoplasia (n = 25; including PanIN2,
PanIN3, and IPMNs), and pancreatic cancer (n = 8). As
shown in Figure 5A and B, the level of AGR2 in pancre-
atic juice was significantly higher in patients with pre-
malignant pancreatic diseases compared to benign dis-
ease controls (p = 0.003). The level of pancreatic juice
Figure 4 Elevation of AGR2. A. Fold-changes of AGR2 in pancreatic 
juice from patients with PanIN3 detected by quantitative proteomics 
analysis in comparison to controls. B. Detection of AGR2 by IHC in neo-
plastic pancreas ducts. Strong staining of AGR2 was detection in the 
neoplastic ducts of PanIN cases a and c (I and II), as well as the neoplas-
tic region of pancreatic cancer (VI). AGR2 was not detected in the nor-
mal pancreas duct (III).
Table 3: Peptides identified from the AGR2 pull-down product
AGR2 Peptide Observed Sequence Position Mass detected PeptideProphet
probability score
KDTKDSRPKLPQTLSR 51-66 1869.04 0.93
DSRPKLPQTLSR 55-66 1396.78 1.00
LPQTLSR 60-66 813.47 0.92
GWGDQLIWTQTYEEALYK 67-84 2200.05 1.00
GWGDQLIWTQTYEEALYKSK 67-86 2415.17 1.00
LAEQFVLLNLVYETTDKHLSPDGQYVPR 120-147 3244.68 1.00
NLVYETTDKHLSPDGQYVPR 128-147 2331.15 1.00
IMFVDPSLTVR 148-158 1276.68 1.00
IM[147]FVDPSLTVR 148-158 1293.83 1.00
ALKLLKTEL 187-195 1027.66 0.99
Note: [147] indicates oxidized methionineChen et al. Molecular Cancer 2010, 9:149
http://www.molecular-cancer.com/content/9/1/149
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AGR2 was also significantly higher in pancreatic cancer
compared to controls (p = 0.03). The median pancreatic
juice AGR2 level was not significantly different between
males and females, different age groups, within subcate-
gories of benign controls and premalignant pancreatic
diseases (all p>0.05, Table 5).
ROC analysis was applied to evaluate the sensitivity and
specificity of AGR2 in distinguishing premalignant and
pancreatic cancer juice samples from benign controls
(Figure 6). At 90% specificity, the AGR2 ELISA achieved
40% sensitivity in discriminating premalignant juice sam-
ples from the control group (Table 6). The area under
curve (AUC) was 0.742. When we compared the ROC
curve of the subset of PanIN3 juice samples to the control
group, the AUC was slightly improved to 0.765. At 90%
specificity, the AGR2 ELISA achieved 67% sensitivity in
discriminating PanIN3 juice samples from the control
group. Pancreatic cancer juice samples achieved a slightly
lower AUC value (AUC = 0.729) and sensitivity than the
premalignant group (Table 6). At 90% specificity, AGR2
had a sensitivity of 25% in discriminating pancreatic can-
cer juice samples from the control group.
Non-correlation of AGR2 levels in pancreatic juice versus 
serum
AGR2 levels were measured by ELISA in six paired serum
and juice samples (all from PanIN patients). AGR2 was
not detectable in any of the six serum samples tested. Of
the corresponding juice samples, five displayed positive
AGR2 levels, ranging from 0.84 ng/ml to 17.91 ng/ml.
Thus, AGR2 levels in pancreatic juice do not correlate
w i t h  A G R 2  l ev e l s  i n  s e ru m .  M o r e o v e r ,  w h e n  w e  c o m -
Table 4: AGR2 ELISA performance characteristics
Recombinant AGR2 Protein (ng/ml) Human Serum Panc. Cell Lysates
40 13.3 4.44 1.48 0.494 0.165 0.055 CFPAC1-1 MiaPaca
All Assays Mean (ng/ml) 40.30 13.20 4.54 1.41 0.48 0.18 0.07 22.00 120.70 14.60
ratio (signal/noise) 3559 1169 401 124 42 15 6.2 195 1065 129
Intra-assay SD (ng/ml) 1.260 0.199 0.079 0.062 0.014 0.008 0.004 1.400 8.300 0.790
CV (%) 3.1 1.5 1.8 4.4 2.9 4.6 5.9 6.2 6.8 5.4
Inter-assay SD (ng/ml) 1.240 0.207 0.081 0.067 0.012 0.008 0.006 3.400 5.100 1.000
CV (%) 3.1 1.6 1.8 4.8 2.6 4.5 9.1 16.0 4.3 6.8
SD: standard deviation; CV: coefficient of variation
Figure 5 A. AGR2 concentration in pancreatic juice as measured by ELISA. CP: chronic pancreatitis. B. Boxplots of AGR2 concentration in pancre-
atic juices from patients with benign diseases (n = 20, including normal and chronic pancreatitis), pre-malignant lesions (n = 25, including PanIN2, 
PanIN3 and IMPNs), and pancreatic cancer (n = 8). Boxplot: the thin box marks out the 25th to 75th percentiles; the line marks the outer part of the 
distribution, and outside dots mark outliers.Chen et al. Molecular Cancer 2010, 9:149
http://www.molecular-cancer.com/content/9/1/149
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pared sera from pancreatic cancer cases and cancer-free
controls, only 1/9 pancreatic cancer sera showed a high
level of AGR2, compared to 0/9 cancer-free controls.
Therefore, AGR2 levels were not significantly different
between pancreatic cancer sera and sera from cancer-free
controls (Figure 7, p = 0.27).
Discussion
AGR2 is a secreted protein initially described in Xenopus
laevis for being differentially expressed in neural develop-
ment [19]. In Xenopus, the AGR2 homologue is critical in
forming anterior structures during embryonic ectoderm
development [20]. The function of AGR2 in human tissue
is largely unknown, but overexpression of AGR2 has been
reported in several cancers, including breast, prostate,
lung and pancreas and in circulating tumor cells [11,21-
25] .  R ec en t  evide nc e  su gg ests  t ha t  A G R 2 can p r om ot e
tumor growth, promote cancer cell survival, cell migra-
tion, and cellular transformation [11,19]. Detection of
AGR2 in these previous studies was primarily performed
on tissue or cell lines using RT-PCR, western blotting or
IHC. One recent study showed that increased AGR2 in
plasma is associated with ovarian cancer[26]. However, to
the best of our knowledge, evaluation of AGR2 protein in
plasma or other biological fluids has not been reported in
pancreatic cancer.
In this study, we first used quantitative proteomics to
identify elevated proteins in pancreatic juice. We found
that AGR2 was elevated in all of the three pre-neoplastic
pancreatic juice samples (PanIN3) analyzed by quantita-
tive proteomics. The AGR2 levels in pancreatic juice cor-
related with its over-expression in matching pancreas
Table 5: Median pancreatic juice AGR2 values by clinical-pathologic parameters
number of case Juice Median
AGR2 (ng/ml)
P
Sex 0.35
Male 19 1.82
Female 30 1.94
Age 0.79
Y (<50) 24 2.09
M (50-70) 17 1.82
O (>70) 10 3.61
Benign 0.12
Sphincter of Oddi 7 0.00
Chronic pancreatitis 11 2.32
Premalignant 0.36
PanIN2 6 2.88
PanIN3 9 14.85
IPMN 10 1.49
Malignant 8 4.93
Figure 6 ROC curves of AGR2 levels in pancreatic juice from pa-
tients with pre-malignant lesions, PanIN3 lesions, and pancreatic 
cancer compared to benign disease controls.Chen et al. Molecular Cancer 2010, 9:149
http://www.molecular-cancer.com/content/9/1/149
Page 11 of 12
tissues. These findings are in concert with previous stud-
ies that have also demonstrated increased expression of
AGR2 in PanIN lesions [11,27] and pancreatic ductal ade-
nocarcinoma tissues [11,23]. Along with these previous
studies, it is evidenced that AGR2 is likely to be secreted
into the pancreatic duct fluid early in pancreatic cancer
progression. However, a recent study found that AGR2 is
localized to the endoplasmic reticulum in intestinal epi-
thelial cells and did not detect AGR2 in secretory gran-
ules or in the intestinal lumen[28]. Thus it is possible that
only a fraction of AGR2 is actually secreted. And this
could explain why pancreatic cancer patients do not have
higher juice AGR2 level than the PanIN patients, while
they have strong AGR2 staining in the cancer tissues. The
mechanism governing AGR2 secretion is currently
unknown.
To evaluate AGR2 levels in pancreatic juice and blood,
we developed an ELISA assay to quantitatively measure
AGR2 levels. We used mass spectrometry to verify that
the monoclonal antibody used in the ELISA was indeed
specific for AGR2. By ELISA, AGR2 levels in the pancre-
atic juice samples from patients with benign pancreatic
disease, premalignant pancreatic neoplasia and pancre-
atic cancer were tested and compared. The pancreatic
juice AGR2 level was significantly elevated in patients
with premalignant lesions and pancreatic cancer com-
pared to control samples. Further ROC analysis sug-
gested that at 90% specificity, the AGR2 ELISA achieved
67% sensitivity in detecting PanIN3 juice samples from
the control group. The ability to detect pancreatic cancer
at an early stage could greatly benefit the patient manage-
ment and improve the survival rate. Currently, it is only
possible to detect PanIN3 histologically. Pancreatic juice
CA19-9 levels could not separate patients with pancreatic
cancer from chronic pancreatitis[29]. Moreover, CA19-9
is not elevated in the blood of PanIN3 patients, thus is not
useful as a PanIN3 biomarker[12]. The discovery of
AGR2 elevation in the pancreatic juice of PanIN3 patients
in this study may provide a future opportunity to develop
and test this candidate as juice biomarker for PanIN3.
While AGR2 levels were significantly elevated in the
pancreatic juice from premalignant and pancreatic cancer
patients, serum levels of AGR2 did not distinguish
patients with premalignant or pancreatic cancer from
control patients. This result supports the view that pan-
creatic juice, due to proximity to the tumor, can be a more
sensitive and specific source for identifying biomarker
candidates associated with pancreatic cancer or pre-can-
cer [30,31].
Conclusion
In this study, we found that AGR2 was significantly ele-
vated in the pancreatic juice from patients with pre-
malignant conditions (PanINs and IPMNs) as well as pan-
creatic cancer compared to control pancreatic juice sam-
ples. AGR2 levels in pancreatic juice could potentially be
used to aide in assessment of high-risk patients undergo-
ing endoscopic procedures.
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